Baidu
map

白春学教授谈肺癌诊治端口前移:重视肺结节早期评估

2016-10-08 MedSci MedSci原创

2016 年 9 月 22-25 日,中华医学会呼吸病学分会(CTS)年会暨第十七次全国呼吸病学学术会议在文化历史名城陕西西安召开。9 月 23 日,中华医学会呼吸病学分会副主任委员、中国肺癌防治联盟主席、《亚太肺结节评估指南》修订委员会主席、上海市呼吸病研究所、上海中山医院呼吸科白春学教授就「亚太肺结节评估指南制定背景」进行了精彩演讲。白春学教授在大会上做报告《亚太肺结节评估指南》修订背景目前,

2016 年 9 月 22-25 日,中华医学会呼吸病学分会(CTS)年会暨第十七次全国呼吸病学学术会议在文化历史名城陕西西安召开。9 月 23 日,中华医学会呼吸病学分会副主任委员、中国肺癌防治联盟主席、《亚太肺结节评估指南》修订委员会主席、上海市呼吸病研究所、上海中山医院呼吸科白春学教授就「亚太肺结节评估指南制定背景」进行了精彩演讲。



白春学教授在大会上做报告

《亚太肺结节评估指南》修订背景

目前,肺癌是世界上发病率及死亡率最高的恶性肿瘤。中国肺癌的发病率在亚太地区处在第一位,男性发病率为 70 例/万-人,女性为 36 例/万-人。为此,在解决我国肺癌发病率、死亡率高的问题上,我们提出了「端口前移」、「重心下沉」、「学术引领」、「智能惠众」的解决办法。「端口前移」是指我们在诊断肺癌时,移到肺癌发病之前——肺结节。需要强调的是:并不是所有的肺结节都会转化为肺癌,肺结节大约有 10% 的是肺癌。中国有 5000 万肺结节患者,因此「端口」前移对预防肺癌相当重要。

2014 年 8 月 23 日,亚洲呼吸科和胸外科医生组成多学科专家组,在香港召开了「亚太肺结节诊治指南」修订会议,白春学教授被选为指南修订委员会主席。根据亚太实际情况,专家组综合国内外及西方的资料,经过一年半的修改,制定了适合亚太的肺结节评估指南,并于 2016 年 3 月在 Chest 杂志正式在线发表。指南根据结节类型分别进行讨论,指南中包含对肺结节患者进行恶性肿瘤的概率估计、开展影像学检查、评估各种替代管理相关风险,及征求患者的意愿进行评估和管理。

《亚太肺结节评估指南》修订要点

1. 未定性结节

所有新发肺结节在确诊之前都称为未定性结节。胸片发现孤立未定性结节需要回顾性分析既往影像学检查;已稳定至少 2 年的未定性肺结节,是否需要对其中的高危者进行年度 CT 检查,需要进行个体化分析;胸片发现孤立性未定性肺结节,需要进行低剂量胸部 CT(建议病灶薄层扫描)检查来明确其特征并评估恶性概率(图 2)。在此需要强调肺结节位置的重要性,因为有些位置的肺结节普通 CT 是看不到的。


未定性结节恶性肿瘤评估模型

2. 实性结节

对于实质性结节首先考虑孤立的(实性结节、纯磨玻璃、混合性)还是多发的,通过智能协助,深度挖掘,规范化预测肿瘤风险,并进行处理。

如果实质性结节为 8~30 mm,需要评估手术风险。若手术风险评估为低中度,可以直接通过非手术活检进行评估;手术风险评估较高的患者采用非手术活检或 CT 随访进行评估。

小于 8 mm 的实质性结节,由于不容易被诊断,一旦长大又容易发生转移,诊断这类患者具有相当的挑战性,中国这类患者的数量在 4000 万以上。对于这类患者要综合考虑是否有肺癌危险因素、同时评估结节的大小及特征,在征求患者的意愿下,根据年度影像学检查(CT 或 PET-CT)的随访结果进行评估。

3. 非实性结节

直径 ≤ 5 mm 的非实性结节,根据临床和患者意愿进行年度 CT 随访;

直径>5 mm 非实性结节,每年 CT 随访评估至少持续 3 年,此后是否进行年度 CT 随访,需要根据临床和患者意愿决定。

对有多个结节的患者需要对每个结节进行评估。另外,在具备电磁导航支气管镜(ENB)新技术的条件下,可以在一次检查操作中对多个较小周边病灶,开展组织活检并进行病理学评估。

肺结节诊断新技术及未来发展方向

介入肺脏病学具有诊断和管理肺结节与时俱进的特征,通过综合影像学、细胞学、支气管镜技术、手术或非手术活检等技术可以提高诊断率并减少风险。

特别需要介绍的是此次亚太肺结节诊治指南将物联网医学的内容写入,推动物联网技术在肺结节监测和诊断中的应用。借助物联网医学能够缩小时间、空间、经验、资源等方面的差别。将来专家可以利用物联网呼吸内镜技术在线对患者进行检查。采用物联网技术进行随访,可以提高患者的随访率。

影像学从二维到三维转变能够精细研究血管的生长状态,有利于对患者的症状进行深度的挖掘。

白春学教授最后总结到,由于亚洲室内外空气污染,非吸烟女性肺腺癌高发。指南中提到的肺癌风险计算公式有限,应考虑到亚洲肉芽肿性疾病高发,以及其它感染性因素引起的肺结节。肺结节患者随访应考虑长期监测,更多使用非手术活检,较少依赖 PET 检查。

白春学教授指出,亚太肺结节评估指南对中国及亚洲肺结节患者具有重要意义,对世界肺结节的、肺癌的防治具有深远影响。鼓励亚洲医生使用本地区的专家共识指南,以形成对肺结节评估的一致性和可重复性。中国执行的战略战术需要物联网医学的精准技术,中国肺癌防治联盟-百千万工程的助力。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-09 知难而进

    继续关注!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-09 知难而进

    谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-09 知难而进

    谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 1e0d99ddm02(暂无匿称)

    分享一下!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1635642, encodeId=894e1635642a2, content=<a href='/topic/show?id=e9c0e1688f9' target=_blank style='color:#2F92EE;'>#白春学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71688, encryptionId=e9c0e1688f9, topicName=白春学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=618122505951, createdName=陆成振, createdTime=Fri Dec 16 11:16:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142341, encodeId=053414234198, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:45 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142340, encodeId=b87c142340fd, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:38 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142339, encodeId=211114233992, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:43:30 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142053, encodeId=06151420534f, content=分享一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160817/IMG57B3C3F6DC2FD8753.jpg, createdBy=81321934679, createdName=1e0d99ddm02(暂无匿称), createdTime=Sat Oct 08 14:51:17 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141977, encodeId=cc8a1419e73b, content=学习了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e291719269, createdName=大旺旺, createdTime=Sat Oct 08 10:37:33 CST 2016, time=2016-10-08, status=1, ipAttribution=)]
    2016-10-08 大旺旺

    学习了啊

    0

相关资讯

白春学:移动医疗创新的价值在于为病人解决多少问题

MedSci:大家好,今天我们请到的是上海市呼吸病学研究所所长,复旦大学附属中山医院呼吸科主任白春学教授。白教授也是本次梅斯医学移动医疗创新大赛的特邀嘉宾之一。移动医疗是新的事物,我们对它肯定会有一些困惑,所以我们想就移动医疗和临床医学相关的问题请教一下白教授。您认为临床医生在移动医疗中扮演着一个什么角色呢?白春学:你这个问题提得非常好,我很愿意回答这个问题。应该讲,在移动医疗中医生发挥主要的

白春学教授在美国胸科协会(ATS)2016年会上作《物联网医学在呼吸系统疾病中的创新运用》专题报告

2016年5月14日周六上午11点至下午4点15分在美国加州旧金山Moscone中心306会议室,成功举办了亚太呼吸学会(APSR)-国际呼吸病学会(ISRD)联合会议,此次会议由世界呼吸病学影响最大的美国胸科协会(ATS)连续第6年在年会中设立亚太地区及中国学者专场,会议由ISRD主席暨中国肺癌防治联盟主席、上海呼吸病研究所所长白春学教授及现任APSR主席Mishima教授联合主持,针对目前全球

讲座预告:5月28日下午16:50-18:00白春学教授国际物联网医学讲座即将在线全程直播

2016年5月28日北京时间16点50分,中国肺癌防治联盟主席,上海市呼吸病研究所所长白春学教授奖出席在荷兰阿姆斯特丹举行的第8界国际社区医疗呼吸病协作组大会,并将做《如果在中国通过云计算和物联网技术开展基于手机平台的电子医疗》讲座,欢迎大家点击“阅读原文”或关注公众号进行在线全程观看。 讲座在线直播地址: http://ipcrgwebcast.eventresult.com 讲座时

白春学教授主编新书《物联网医学》正式出版!

内  容  简  介本书邀请国内外多位物联网医学基础和临床相关专家, 详细介绍目前最先进的物联网医学基础理论和应用进展。 全书共分 5 篇 27 章, 110 余例图示, 内容包括物联网医学的诞生、 物联网医学的基本组成、 物联网医学的应用、 物联网医学的卫生经济学基础和物联网医学的潜在空间, 运用现代科学技术为国民的健康实现无缝隙的跟踪服务。 全书所述内容不但国内超

Baidu
map
Baidu
map
Baidu
map